Further Development of an Exhaled microRNA Biomarker of Lung Cancer Risk
Abstract
We seek to devise a non-invasive airway based exhaled microRNA metric for lung cancer risk, initial work to be tested in a case control study. We expanded the microRNA panel to ~30microRNAs, and expanded the cohort beyond Einstein-Montefiore/Bronx to include Bronx /J Peters VAH clinic-based recruits, in a case-control study. We also expanded the assessment of lung cancer subjects to also include limited (3-month) prospective follow-up of non-cancer controls in order to minimize control contamination/misclassification, and improved matching on age, smoking status, and underlying COPD (initial n~90 versus n~90 controls). In essence we were able to detect a discriminant signature from exhaled microRNAs, whereby discriminant accuracy over and above clinical criteria alone, was improved by 3-8.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2017
- Accession Number
- AD1051161
Entities
People
- Simon D Spivack
Organizations
- Albert Einstein College of Medicine